NEUROCRINE BIOSCIENCES INC — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+60.2% +$146M
$388M
Free Cash Flow↑+65.1% +$153M
$388M
Investing Cash Flow↑+125.8% +$69M
$14M
Financing Cash Flow
$37M
Capex↑+63.0% +$5M
$13M
Stock Buybacks↓-100.0% -$300M
$0
Stock-Based Comp↓-11.7% -$8M
$59M
D&A↑+3.2% +$200K
$6M
SBC Allocated Expense↑+14.9% +$22M
$173M
SBC Unrecognized Cost
—